skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting ß2-agonists: an observational study in UK specialist care

Rapid Communication

(550) Views  (104) Full article downloads

Authors: Thomas M, Haughney J, Price D


Video presented by Dr Mike Thomas
Views: 53

Published Date December 2011 Volume 2011:2 Pages 25 - 31
DOI: http://dx.doi.org/10.2147/POR.S24674

Mike Thomas, John Haughney, David Price
Centre of Academic Primary Care, School of Medicine and Dentistry, University of Aberdeen, Foresterhill Health Centre, Aberdeen, UK

Purpose: Recent real-world studies have demonstrated that asthma control remains suboptimal in many patients. The aim of this study was to evaluate physicians’ perceptions of the effectiveness of combination therapy with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) in routine clinical practice.
Methods: In November 2009, UK respiratory specialists were invited by medeConnect Healthcare Insight to complete a survey on the effectiveness of different single- or dual-inhaler combinations of an ICS and a LABA in the context of asthma management. Respondents were permitted to specify combinations of available ICSs and LABAs, based on their knowledge and experience of the individual components. Questions elicited both unprompted free-text responses and prompted responses selected from a list of options.
Results: A total of 98 physicians completed the survey, of whom 82 (84%) gave permission to publish their data. The majority of respondents (63%) were consultants and 57% reported a caseload of more than 40 patients with asthma or chronic obstructive pulmonary disease per month. Fluticasone and formoterol were considered to be the most effective combination for the treatment of asthma (37% unprompted, 41% prompted), followed by budesonide and formoterol (22% unprompted, 24% prompted). The most common reasons for choosing specific combinations were: rapid onset of action (60%), high potency of the ICS (39%), efficacy (15%), experience of prescribing (13%), clinical evidence (12%), and long-lasting effect (10%). Key properties of the preferred fluticasone and formoterol combination were rapid onset of action and high potency of the ICS (79% for both).
Conclusion: The results of this survey suggest that the ICS and LABA combination considered most effective by UK physicians in the management of asthma is fluticasone and formoterol, which is not currently available as a single-inhaler combination. The development of new single-inhaler combinations of ICSs and LABAs may improve real-world asthma management.

Keywords: asthma, LABA, ICS, combination, effectiveness, real-world






Readers of this article also read:

Re-defining outcomes and re-evaluating remission in inflammatory bowel disease: Assessing key evidence
Rhinosinusitis in COPD: symptoms, mucosal changes, nasal lavage cells and eicosanoids
Proliferating cell nuclear antigen (PCNA) allows the automatic identification of follicles in microscopic images of human ovarian tissue
Profile of ipilimumab and its role in the treatment of metastatic melanoma
The role of S-1 in the treatment of gastric cancer
Is advertising ethical for dentists? An insight into the Indian scenario
Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease
Pragmatic research and outcomes in asthma and COPD
Mixed dyslipidemias in primary care patients in France